KR100979025B1 - 바이러스, 바이러스 단리물 및 백신의 생산 - Google Patents
바이러스, 바이러스 단리물 및 백신의 생산 Download PDFInfo
- Publication number
- KR100979025B1 KR100979025B1 KR1020047008520A KR20047008520A KR100979025B1 KR 100979025 B1 KR100979025 B1 KR 100979025B1 KR 1020047008520 A KR1020047008520 A KR 1020047008520A KR 20047008520 A KR20047008520 A KR 20047008520A KR 100979025 B1 KR100979025 B1 KR 100979025B1
- Authority
- KR
- South Korea
- Prior art keywords
- influenza
- cells
- influenza virus
- virus particles
- cell
- Prior art date
Links
- 230000003612 virological effect Effects 0.000 title claims abstract description 46
- 238000004519 manufacturing process Methods 0.000 title claims description 31
- 229960005486 vaccine Drugs 0.000 title claims description 29
- 241000700605 Viruses Species 0.000 title abstract description 55
- 239000002245 particle Substances 0.000 claims abstract description 98
- 238000000034 method Methods 0.000 claims abstract description 81
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 28
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 28
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 28
- 210000004027 cell Anatomy 0.000 claims description 209
- 241000712461 unidentified influenza virus Species 0.000 claims description 94
- 108090000141 Sialyltransferases Proteins 0.000 claims description 71
- 102000003838 Sialyltransferases Human genes 0.000 claims description 70
- 206010022000 influenza Diseases 0.000 claims description 65
- 230000013595 glycosylation Effects 0.000 claims description 18
- 238000006206 glycosylation reaction Methods 0.000 claims description 18
- 101710154606 Hemagglutinin Proteins 0.000 claims description 16
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 16
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 16
- 101710176177 Protein A56 Proteins 0.000 claims description 16
- 239000001963 growth medium Substances 0.000 claims description 16
- 230000001902 propagating effect Effects 0.000 claims description 16
- 241000282412 Homo Species 0.000 claims description 14
- 241000271566 Aves Species 0.000 claims description 13
- 230000000890 antigenic effect Effects 0.000 claims description 12
- 210000005260 human cell Anatomy 0.000 claims description 11
- 238000012258 culturing Methods 0.000 claims description 10
- 241000701161 unidentified adenovirus Species 0.000 claims description 7
- 102000005348 Neuraminidase Human genes 0.000 claims description 6
- 108010006232 Neuraminidase Proteins 0.000 claims description 6
- 241000282887 Suidae Species 0.000 claims description 6
- 241000282898 Sus scrofa Species 0.000 claims description 5
- 238000003306 harvesting Methods 0.000 claims description 5
- 230000000415 inactivating effect Effects 0.000 claims description 2
- 102000035123 post-translationally modified proteins Human genes 0.000 abstract 1
- 108091005626 post-translationally modified proteins Proteins 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 18
- 239000006228 supernatant Substances 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 15
- 230000035755 proliferation Effects 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 14
- 235000013601 eggs Nutrition 0.000 description 13
- 239000000185 hemagglutinin Substances 0.000 description 11
- 102000004357 Transferases Human genes 0.000 description 10
- 108090000992 Transferases Proteins 0.000 description 10
- 230000002018 overexpression Effects 0.000 description 10
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 9
- 102000003951 Erythropoietin Human genes 0.000 description 8
- 108090000394 Erythropoietin Proteins 0.000 description 8
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 229940105423 erythropoietin Drugs 0.000 description 8
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 7
- 230000000644 propagated effect Effects 0.000 description 7
- 238000004448 titration Methods 0.000 description 7
- 102000003886 Glycoproteins Human genes 0.000 description 6
- 108090000288 Glycoproteins Proteins 0.000 description 6
- 229930193140 Neomycin Natural products 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 229960004927 neomycin Drugs 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 230000035772 mutation Effects 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 208000003098 Ganglion Cysts Diseases 0.000 description 2
- 241000712431 Influenza A virus Species 0.000 description 2
- 241001500351 Influenzavirus A Species 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- 241001505332 Polyomavirus sp. Species 0.000 description 2
- 240000006028 Sambucus nigra Species 0.000 description 2
- 235000003142 Sambucus nigra Nutrition 0.000 description 2
- 208000005400 Synovial Cyst Diseases 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000008995 european elder Nutrition 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000037797 influenza A Diseases 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 125000005629 sialic acid group Chemical group 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
- 108010057856 Adenovirus E2 Proteins Proteins 0.000 description 1
- 101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101150039660 HA gene Proteins 0.000 description 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 241001521394 Maackia amurensis Species 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000725681 Swine influenza virus Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000013354 cell banking Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 210000004252 chorionic villi Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 102000044890 human EPO Human genes 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 125000005630 sialyl group Chemical group 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (41)
- 인플루엔자 바이러스 입자를 생산하기 위한 방법으로, 상기 방법은:- 배양 배지에서 세포를 인플루엔자 바이러스 입자와 접촉시켜 상기 인플루엔자 바이러스 입자에 의하여 상기 세포를 감염시키고; 그리고- 상기 세포를 배양하여 상기 인플루엔자 바이러스 입자를 증식시키는 단계를 포함하고,상기 세포는 알파2,6 시알릴트랜스퍼라제 또는 그것의 기능적 등가물을 암호화하는 핵산을 과발현하는 것인 방법.
- 제 1항에 있어서, 상기 알파2,6 시알릴트랜스퍼라제는 인간 알파2,6 시알릴트랜스퍼라제인 방법.
- 인플루엔자 바이러스 입자를 생산하기 위한 방법으로, 상기 방법은:- 배양 배지에서 세포를 인플루엔자 바이러스 입자와 접촉시켜 상기 인플루엔자 바이러스 입자에 의하여 상기 세포를 감염시키고; 그리고- 상기 세포를 배양하여 상기 인플루엔자 바이러스 입자를 증식시키는 단계를 포함하고,상기 세포는 알파2,3 시알릴트랜스퍼라제 또는 그것의 기능적 등가물을 암호화하는 핵산을 과발현하는 것인 방법.
- 제 3항에 있어서, 상기 알파2,3 시알릴트랜스퍼라제는 인간 알파2,3 시알릴트랜스퍼라제인 방법.
- 삭제
- 제 1항 내지 제 4항 중 어느 한 항에 있어서, 상기 인플루엔자 바이러스 입자는 인플루엔자 단리물(isolate)에 존재하는 방법.
- 제 6항에 있어서, 상기 인플루엔자 단리물은 하나 이상의 인플루엔자-감염된 포유동물 개체로부터 얻어지는 방법.
- 제 7항에 있어서, 상기 인플루엔자-감염된 포유동물 개체는 인간 또는 돼지인 방법.
- 제 6항에 있어서, 상기 인플루엔자 단리물은 하나 이상의 인플루엔자-감염된 새로부터 얻어지는 방법.
- 제 1항 내지 제 4항 또는 제 7항 내지 제 9항 중 어느 한 항에 있어서, 상기 세포는 아데노바이러스 유래의 E1으로 형질전환되는 방법.
- 제 10항에 있어서, 상기 세포는 인간 세포인 방법.
- 제 11항에 있어서, 상기 인간 세포는 PER.C6 또는 그것의 유도체인 방법.
- 제 1항 내지 제 4항 또는 제 7항 내지 제 9항 중 어느 한 항에 있어서, 시알릴트랜스퍼라제를 암호화하는 상기 핵산은 상기 세포에 이종성인 방법.
- 제 13항에 있어서, 시알릴트랜스퍼라제 또는 그것의 기능적 등가물을 암호화하는 상기 핵산은 상기 세포의 게놈으로 통합되는 방법.
- 백신을 제조하는 방법으로, 상기 방법은:- 제 1항 내지 제 4항 또는 제 7항 내지 제 9항 중 어느 한 항에 따른 인플루엔자 바이러스 입자를 생산하는 단계; 및- 생산된 인플루엔자 바이러스 입자를 비활성화하는 단계를 포함하는 방법.
- 제 15항에 있어서, 상기 방법은 추가로:- 항원성 부분을 제공하기 위하여 생산된 상기 인플루엔자 바이러스 입자를 처리하는 단계; 및- 하나 이상의 항원성 부분을 얻는 단계를 포함하는 방법.
- 제 16항에 있어서, 상기 항원성 부분은 헤마글루티닌 단백질 또는 그것의 일부, 또는 뉴라미니다제 단백질 또는 그것의 일부, 또는 헤마글루티닌 단백질과 뉴라미니다제 단백질 또는 그것들의 일부를 포함하는 방법.
- 삭제
- 삭제
- 알파2,6 시알릴트랜스퍼라제 또는 그것의 기능성 부분을 과발현하는 세포를 사용하여 인플루엔자 바이러스 입자를 증식하는 방법.
- 알파2,3 시알릴트랜스퍼라제 또는 그것의 기능성 부분을 과발현하는 세포를 사용하여 인플루엔자 바이러스 입자를 생산하는 방법.
- 삭제
- 제 20항 또는 제 21항에 있어서, 상기 인플루엔자 바이러스 입자는 하나 이상의 인플루엔자-감염된 포유동물 개체로부터 얻어진 인플루엔자 단리물에 존재하는 것인 방법.
- 제 23항에 있어서, 상기 인플루엔자-감염된 포유동물 개체는 인간 또는 돼지인 방법.
- 제 20항 또는 제 21항에 있어서, 상기 인플루엔자 바이러스 입자는 하나 이상의 인플루엔자-감염된 새로부터 얻어진 인플루엔자 단리물에 존재하는 것인 방법.
- 삭제
- 인플루엔자 단리물에 존재하는 예비결정된 인플루엔자 바이러스 입자 세트의 선별적인 증식 방법으로, 상기 예비결정된 인플루엔자 바이러스 입자 세트는 수용체에 존재하는 특이적 당화 모이어티(moiety)에 친화성을 가지고, 상기 인플루엔자 단리물은 상기 세트에 더하여 예비결정된 특이성을 갖지 않는 인플루엔자 바이러스 입자를 추가로 포함하고, 상기 방법은:- 상기 세트에 존재하는 하나 이상의 인플루엔자 바이러스 입자에 의하여 상기 세포를 감염시키기 위하여, 배양 배지에서 상기 인플루엔자 단리물과 함께, 상기 특이적 당화 모이어티를 포함하는 상기 수용체를 발현하고 노출할 수 있는 세포를 인큐베이션하는 단계;- 상기 인플루엔자 바이러스 입자를 증식시키기 위하여 상기 세포를 배양하는 단계; 및- 상기 세포, 또는 상기 배양 배지, 또는 상기 세포와 상기 배양 배지로부터 생산된 바이러스 입자를 수확하는 단계를 포함하고,상기 당화 모이어티는 SAalpha2,6Gal 잔기를 포함하고, 상기 세포는 알파2,6 시알릴트랜스퍼라제를 과발현하는 것인 방법.
- 인플루엔자 단리물에 존재하는 예비결정된 인플루엔자 바이러스 입자 세트의 선별적인 증식 방법으로, 상기 예비결정된 인플루엔자 바이러스 입자 세트는 수용체에 존재하는 특이적 당화 모이어티(moiety)에 친화성을 가지고, 상기 인플루엔자 단리물은 상기 세트에 더하여 예비결정된 특이성을 갖지 않는 인플루엔자 바이러스 입자를 추가로 포함하고, 상기 방법은:- 상기 세트에 존재하는 하나 이상의 인플루엔자 바이러스 입자에 의하여 상기 세포를 감염시키기 위하여, 배양 배지에서 상기 인플루엔자 단리물과 함께, 상기 특이적 당화 모이어티를 포함하는 상기 수용체를 발현하고 노출할 수 있는 세포를 인큐베이션하는 단계;- 상기 인플루엔자 바이러스 입자를 증식시키기 위하여 상기 세포를 배양하는 단계; 및- 상기 세포, 또는 상기 배양 배지, 또는 상기 세포와 상기 배양 배지로부터 생산된 바이러스 입자를 수확하는 단계를 포함하고,상기 당화 모이어티는 SAalpha2,3Gal 잔기를 포함하고, 상기 세포는 알파2,3 시알릴트랜스퍼라제를 과발현하는 것인 방법.
- 삭제
- 삭제
- 제 27항 또는 제 28항에 있어서, 상기 인플루엔자 단리물은 하나 이상의 인플루엔자-감염된 인간, 돼지 또는 새로부터 얻어지는 방법.
- 제 27항 또는 제 28항에 있어서, 상기 세포는 아데노바이러스 유래의 E1으로 형질전환되는 방법.
- 제 32항에 있어서, 상기 세포는 인간 세포인 방법.
- 제 33항에 있어서, 상기 인간 세포는 PER.C6 또는 그것의 유도체인 방법.
- 제 27항 또는 제 28항에 있어서, 상기 세포는 상기 세포에 이종성인 시알릴트랜스퍼라제를 암호화하는 핵산을 포함하는 방법.
- 제 35항에 있어서, 시알릴트랜스퍼라제를 암호화하는 상기 핵산은 상기 세포의 게놈으로 통합되는 방법.
- 삭제
- 삭제
- 삭제
- 알파2,6 시알릴트랜스퍼라제 또는 알파2,3 시알릴트랜스퍼라제를 암호화하는 이종성 핵산을 포함하는 단리된 인간 세포를 사용하여 인플루엔자 바이러스 입자를 선별적으로 증식하는 방법.
- 삭제
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/NL2001/000892 WO2003048197A1 (en) | 2001-12-07 | 2001-12-07 | Production and of viruses, viral isolates and vaccines |
NLPCT/NL01/00892 | 2001-12-07 | ||
EP02075327 | 2002-01-25 | ||
EP02075327.3 | 2002-01-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050044677A KR20050044677A (ko) | 2005-05-12 |
KR100979025B1 true KR100979025B1 (ko) | 2010-08-30 |
Family
ID=26077595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047008520A KR100979025B1 (ko) | 2001-12-07 | 2002-12-09 | 바이러스, 바이러스 단리물 및 백신의 생산 |
Country Status (13)
Country | Link |
---|---|
US (2) | US7504248B2 (ko) |
EP (1) | EP1465987B1 (ko) |
JP (1) | JP4480398B2 (ko) |
KR (1) | KR100979025B1 (ko) |
CN (1) | CN100547069C (ko) |
AT (1) | ATE384785T1 (ko) |
AU (1) | AU2002351444B2 (ko) |
CA (1) | CA2468957C (ko) |
DE (1) | DE60224843T2 (ko) |
ES (1) | ES2297028T3 (ko) |
NZ (1) | NZ533124A (ko) |
PT (1) | PT1465987E (ko) |
WO (1) | WO2003048348A2 (ko) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69638058D1 (de) | 1995-06-15 | 2009-11-26 | Crucell Holland Bv | Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie |
US6783980B2 (en) * | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US7604960B2 (en) | 1999-04-15 | 2009-10-20 | Crucell Holland B.V. | Transient protein expression methods |
US7297680B2 (en) | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
US8236561B2 (en) | 1999-04-15 | 2012-08-07 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
US6855544B1 (en) | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
US20050164386A1 (en) * | 1999-04-15 | 2005-07-28 | Uytdehaag Alphonsus G. | Overexpression of enzymes involved in post-translational protein modifications in human cells |
US7527961B2 (en) | 1999-11-26 | 2009-05-05 | Crucell Holland B.V. | Production of vaccines |
US7521220B2 (en) * | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
US7192759B1 (en) | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
US7767643B2 (en) | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
EP1465987B1 (en) | 2001-12-07 | 2008-01-23 | Crucell Holland B.V. | Production of viruses, viral isolates and vaccines |
SG156535A1 (en) * | 2002-12-17 | 2009-11-26 | Crucell Holland Bv | Recombinant viral-based malaria vaccines |
CA2520891C (en) | 2003-05-09 | 2014-07-08 | Crucell Holland B.V. | Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom |
US8592197B2 (en) * | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
US8992939B2 (en) | 2003-07-11 | 2015-03-31 | Novavax, Inc. | Highly efficient influenza matrix (M1) proteins |
US8506967B2 (en) | 2003-07-11 | 2013-08-13 | Novavax, Inc. | Functional influenza virus like particles (VLPs) |
US8080255B2 (en) | 2003-07-11 | 2011-12-20 | Novavax Inc. | Functional influenza virus like particles (VLPs) |
BRPI0518146A (pt) * | 2004-10-14 | 2008-10-28 | Crucell Holland Bv | kit de partes, uso de um adenovìrus recombinante defectivo na replicação, e, método de vacinação de um mamìfero para a infecção por malária |
US7670837B2 (en) * | 2004-12-23 | 2010-03-02 | Medimmune, Llc | Non-tumorigenic MDCK cell line for propagating viruses |
AU2007347716B2 (en) | 2006-09-15 | 2013-06-20 | Medimmune, Llc | MDCK cell lines supporting viral growth to high titers and bioreactor process using the same |
CA2679703A1 (en) * | 2007-03-02 | 2008-09-12 | Japan Tobacco, Inc. | A novel .beta.-galactoside-.alpha.2,6-sialyltransferase, a gene encoding thereof, and a method for enhancing enzyme activity |
US20120039939A1 (en) * | 2008-04-11 | 2012-02-16 | The Johns Hopkins University | Compositions and methods for vaccine and virus production |
TWI488640B (zh) | 2008-04-16 | 2015-06-21 | Ferring Int Ct Sa | 藥學製劑 |
EP2296701A1 (en) * | 2008-06-11 | 2011-03-23 | Flugen, Inc. | Cell-based systems for producing influenza vaccines |
CN103952376A (zh) | 2008-09-24 | 2014-07-30 | 米迪缪尼有限公司 | 培养细胞、增殖和纯化病毒的方法 |
AU2010244592B2 (en) * | 2009-04-23 | 2016-05-19 | Janssen Vaccines & Prevention B.V. | Recombinant human alpha1-antitrypsin |
GB2471093A (en) | 2009-06-17 | 2010-12-22 | Cilian Ag | Viral protein expression in ciliates |
CN102559599A (zh) * | 2010-12-08 | 2012-07-11 | 吉林大学 | Vero-SIAT1细胞系及其应用 |
CN102175849B (zh) * | 2010-12-22 | 2013-07-03 | 江苏出入境检验检疫局动植物与食品检测中心 | 一种快速检测猪瘟抗体的试剂盒及其制备方法 |
MX2013006234A (es) * | 2011-01-06 | 2013-08-01 | Univ Johns Hopkins | Metodo para la produccion de glicoproteinas recombinantes con semivida en circulacion incrementada en celulas de mamifero. |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000063403A2 (en) * | 1999-04-15 | 2000-10-26 | Crucell Holland B.V. | Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
US4703008A (en) * | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
FR2573436B1 (fr) | 1984-11-20 | 1989-02-17 | Pasteur Institut | Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins |
IL77081A (en) | 1984-12-04 | 1999-10-28 | Genetics Inst | AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin |
US4835260A (en) * | 1987-03-20 | 1989-05-30 | Genetics Institute, Inc. | Erythropoietin composition |
US5192539A (en) * | 1988-07-21 | 1993-03-09 | Akzo N.V. | Infectious bursal disease virus production in continuous cell lines |
US5047335A (en) * | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
GB8900483D0 (en) * | 1989-01-10 | 1989-03-08 | Celltech Ltd | Recombinant dna method |
DE3923963A1 (de) * | 1989-07-20 | 1991-01-31 | Behringwerke Ag | Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung |
US5856298A (en) * | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
DE69125292T2 (de) | 1991-08-01 | 1997-09-25 | Fond Nat Transfusion Sanguine | Expression in nicht-tumorbildenden menschlichen Lymphoblasten Zellinien mit einem integrierenden Vektor |
US5384249A (en) * | 1991-12-17 | 1995-01-24 | Kyowa Hakko Kogyo Co., Ltd. | α2→3 sialyltransferase |
ZA946122B (en) | 1993-08-17 | 1995-03-20 | Amgen Inc | Erythropoietin analogs |
US5631158A (en) * | 1993-10-25 | 1997-05-20 | Creative Biomolecules, Inc. | Methods and compositions for high protein production from non-native DNA |
US5773569A (en) * | 1993-11-19 | 1998-06-30 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
US5830851A (en) * | 1993-11-19 | 1998-11-03 | Affymax Technologies N.V. | Methods of administering peptides that bind to the erythropoietin receptor |
US5789247A (en) * | 1994-04-01 | 1998-08-04 | Ballay; Annick | Expression in non-tumoral human lymphoblastoid lines with an integrative vector |
US5610043A (en) | 1994-04-28 | 1997-03-11 | The United States Of America As Represented By The Department Of Health And Human Services | Human prostatic cell lines immortalized by adenovirus 12-simian virus 40 (AD12/SV40) hybrid virus |
US5767078A (en) * | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
DE69638058D1 (de) | 1995-06-15 | 2009-11-26 | Crucell Holland Bv | Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie |
US5989805A (en) | 1995-10-27 | 1999-11-23 | Board Of Trustees Operating Michigan State University | Immortal avian cell line to grow avian and animal viruses to produce vaccines |
US6472204B1 (en) * | 1995-11-13 | 2002-10-29 | Kiyozo Asada | Methods for retroviral mediated gene transfer employing molecules, or mixtures thereof, containing retroviral binding domains and target cell binding domains |
US5835382A (en) * | 1996-04-26 | 1998-11-10 | The Scripps Research Institute | Small molecule mimetics of erythropoietin |
WO1998018926A1 (en) | 1996-10-25 | 1998-05-07 | G.D. Searle & Co. | Circularly permuted erythropoietin receptor agonists |
JP2000509614A (ja) | 1997-03-04 | 2000-08-02 | バクスター インターナショナル インコーポレイテッド | アデノウイルスe1−相補性細胞系 |
WO1999066041A1 (en) * | 1998-06-16 | 1999-12-23 | Human Genome Sciences, Inc. | 94 human secreted proteins |
DE69829189T2 (de) | 1997-03-27 | 2006-02-16 | The University Of British Columbia, Vancouver | Insekten-expressionsvektoren |
CA2221819A1 (en) * | 1997-03-27 | 1998-09-27 | Thomas A. Gigliatti | Insect expression vectors |
CN1151258C (zh) | 1997-07-23 | 2004-05-26 | 罗切诊断学有限公司 | 通过内源基因活化制备促红细胞生成素 |
US6670188B1 (en) * | 1998-04-24 | 2003-12-30 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
AU784550B2 (en) | 1999-04-13 | 2006-05-04 | Kenneth S. Warren Institute, Inc., The | Modulation of excitable tissue function by peripherally administered erythropoietin |
US20050164386A1 (en) | 1999-04-15 | 2005-07-28 | Uytdehaag Alphonsus G. | Overexpression of enzymes involved in post-translational protein modifications in human cells |
WO2003048197A1 (en) | 2001-12-07 | 2003-06-12 | Crucell Holland B.V. | Production and of viruses, viral isolates and vaccines |
US6855544B1 (en) * | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
US7297680B2 (en) | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
US6492169B1 (en) * | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
US6558948B1 (en) * | 1999-11-23 | 2003-05-06 | Stefan Kochanek | Permanent amniocytic cell line, its production and use for the production of gene transfer vectors |
US7521220B2 (en) | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
US7192759B1 (en) | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
EP1103610A1 (en) | 1999-11-26 | 2001-05-30 | Introgene B.V. | Production of vaccines from immortalised mammalian cell lines |
PA8536201A1 (es) | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
BR0213402A (pt) | 2001-10-29 | 2004-10-13 | Crucell Holland Bv | Métodos para identificar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para selecionar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para se obter uma célula de mamìfero a partir de uma população heterogênea de células, e para produzir uma molécula proteinácea, composição farmaceuticamente aceitável, eritropoietina recombinantemente produzida, usos de uma célula de mamìfero, da eritropoietina recombinantemente produzida, e de uma composição de moléculas semelhantes à eritropoietina, preparação farmacêutica, método para o tratamento preventivo e/ou terapêutico de um distúrbio, composição de moléculas semelhates à eritropoietina, métodos para produzir, em uma célula de mamìfero, moléculas proteináceas, para produzir uma fração enriquecida em uma molécula proteinácea, e para fracionar uma mistura que contém moléculas proteináceas, fração, e, usos de uma fração ou composição, e de eritropoietina recombinantemente produzìvel em uma célula de mamìfero |
EP1465987B1 (en) * | 2001-12-07 | 2008-01-23 | Crucell Holland B.V. | Production of viruses, viral isolates and vaccines |
US20050048038A1 (en) | 2001-12-17 | 2005-03-03 | Jones David Halford Ashton | Efficient production of f(ab')2 fragments in mammalian cells |
NZ537306A (en) | 2002-07-01 | 2008-11-28 | Kenneth S Warren Inst Inc | Compositions comprising mutein recombinant tissue protective cytokines having one or more amino acid substitutions facilitating transport of a molecule via transcytosis across an endothelial cell barrier |
AU2003288273A1 (en) | 2002-10-23 | 2004-05-13 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
SG156535A1 (en) | 2002-12-17 | 2009-11-26 | Crucell Holland Bv | Recombinant viral-based malaria vaccines |
CA2520891C (en) | 2003-05-09 | 2014-07-08 | Crucell Holland B.V. | Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom |
BRPI0518146A (pt) | 2004-10-14 | 2008-10-28 | Crucell Holland Bv | kit de partes, uso de um adenovìrus recombinante defectivo na replicação, e, método de vacinação de um mamìfero para a infecção por malária |
-
2002
- 2002-12-09 EP EP02786227A patent/EP1465987B1/en not_active Expired - Lifetime
- 2002-12-09 US US10/497,832 patent/US7504248B2/en not_active Expired - Lifetime
- 2002-12-09 AU AU2002351444A patent/AU2002351444B2/en not_active Ceased
- 2002-12-09 NZ NZ533124A patent/NZ533124A/en not_active IP Right Cessation
- 2002-12-09 KR KR1020047008520A patent/KR100979025B1/ko active IP Right Grant
- 2002-12-09 JP JP2003549527A patent/JP4480398B2/ja not_active Expired - Lifetime
- 2002-12-09 ES ES02786227T patent/ES2297028T3/es not_active Expired - Lifetime
- 2002-12-09 DE DE60224843T patent/DE60224843T2/de not_active Expired - Lifetime
- 2002-12-09 AT AT02786227T patent/ATE384785T1/de active
- 2002-12-09 CN CNB028243633A patent/CN100547069C/zh not_active Expired - Fee Related
- 2002-12-09 WO PCT/NL2002/000804 patent/WO2003048348A2/en active IP Right Grant
- 2002-12-09 CA CA2468957A patent/CA2468957C/en not_active Expired - Lifetime
- 2002-12-09 PT PT02786227T patent/PT1465987E/pt unknown
-
2007
- 2007-07-16 US US11/879,422 patent/US8802417B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000063403A2 (en) * | 1999-04-15 | 2000-10-26 | Crucell Holland B.V. | Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein |
Non-Patent Citations (1)
Title |
---|
Vaccine, vol.19, pp.2716-1721.(2001.03.21.)* |
Also Published As
Publication number | Publication date |
---|---|
US8802417B2 (en) | 2014-08-12 |
JP2005511051A (ja) | 2005-04-28 |
DE60224843D1 (de) | 2008-03-13 |
JP4480398B2 (ja) | 2010-06-16 |
CN100547069C (zh) | 2009-10-07 |
US20050123564A1 (en) | 2005-06-09 |
US20080050403A1 (en) | 2008-02-28 |
CA2468957A1 (en) | 2003-06-12 |
CA2468957C (en) | 2011-07-12 |
EP1465987B1 (en) | 2008-01-23 |
NZ533124A (en) | 2005-11-25 |
AU2002351444A1 (en) | 2003-06-17 |
PT1465987E (pt) | 2008-04-15 |
AU2002351444B2 (en) | 2008-02-21 |
ATE384785T1 (de) | 2008-02-15 |
DE60224843T2 (de) | 2009-01-08 |
KR20050044677A (ko) | 2005-05-12 |
WO2003048348A2 (en) | 2003-06-12 |
EP1465987A2 (en) | 2004-10-13 |
WO2003048348A3 (en) | 2003-12-11 |
US7504248B2 (en) | 2009-03-17 |
CN1599794A (zh) | 2005-03-23 |
ES2297028T3 (es) | 2008-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100979025B1 (ko) | 바이러스, 바이러스 단리물 및 백신의 생산 | |
JP6352974B2 (ja) | ワクチンのための高力価組み換えインフルエンザ・ウィルス | |
KR100683374B1 (ko) | 백신의 제조 | |
Robertson et al. | Alterations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs | |
JP5666905B2 (ja) | ヘマグルチニンポリペプチド中に変化を有するインフルエンザbウイルス | |
KR100708593B1 (ko) | 발육란 생산성이 우수한 저병원성 h9n2 아형 조류인플루엔자 바이러스 | |
JP2009297040A (ja) | 低温適応性ウマインフルエンザウィルス | |
JP6599316B2 (ja) | 改善されたウイルス産生のためのトリ細胞 | |
Barman et al. | Manipulation of neuraminidase packaging signals and hemagglutinin residues improves the growth of A/Anhui/1/2013 (H7N9) influenza vaccine virus yield in eggs | |
CN108888761B (zh) | 表达h7n9亚型禽流感病毒血凝素蛋白的重组杆状病毒灭活疫苗及其制备方法与应用 | |
WO2003048197A1 (en) | Production and of viruses, viral isolates and vaccines | |
CN108348596A (zh) | 用牛免疫缺陷病毒Gag蛋白的重组病毒样颗粒 | |
EP2975119B1 (en) | Cell strain having increased virus production ability and production method therefor | |
Al-Mubarak et al. | Identification of morphological differences between avian influenza A viruses grown in chicken and duck cells | |
GB2437799A (en) | Defective interfering (DI) virus | |
Feng et al. | H9 subtype influenza vaccine in MDCK single‐cell suspension culture with stable expression of TMPRSS2: Generation and efficacy evaluation | |
KR102098585B1 (ko) | 교차 면역원성을 갖는 h2 아형 인플루엔자 바이러스 및 이를 포함하는 백신 | |
Lu et al. | Optimization of cell culture for H9N2 subtype AIV and establishment of high-yield cell strain | |
KR101423695B1 (ko) | 발육계란 고증식성, 무병원성 인플루엔자 바이러스 제작용 재조합 발현 벡터 | |
Marzio et al. | Production of viruses, viral isolates and vaccines | |
Wu et al. | Immunogenicity and efficacy of a recombinant adenovirus expressing hemagglutinin from the H5N1 subtype of swine influenza virus in mice | |
AU2008265760B2 (en) | Influenza B viruses having alterations in the hemaglutinin polypeptide | |
TWI494430B (zh) | 製備與真實流感病毒粒子高度相似的流感類病毒顆粒之轉殖基因哺乳動物細胞表現系統 | |
UA110195C2 (en) | Method for testing extraneous agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130809 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20140806 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20150730 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20160727 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20170804 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20180730 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20190729 Year of fee payment: 10 |